Want to see APRE full AI Analyst Report?
Top Page
Aprea Therapeutics
(NASDAQ:APRE)
Select Model
Select Model
Rating:52Neutral
Price Target:
$0.85
▼(-10.95% Downside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by weak financial performance—zero revenue, ongoing losses, and continued cash burn—despite a debt-free balance sheet. Technical signals are moderately positive (price above key moving averages with positive MACD), and recent corporate updates (expanded IP and pipeline progress with stated cash runway) are constructive. Valuation remains challenged due to losses (negative P/E) and no indicated dividend yield.
Positive Factors
Expanded intellectual property protection
Broad issued and pending patent coverage can protect Aprea’s precision-oncology assets from competition and support future licensing or commercialization. Potential exclusivity into 2045–2047 strengthens the long-term strategic value of successful clinical candidates.
Negative Factors
No recurring product revenue
Aprea has no established commercial product or recurring revenue stream, so its long-term prospects depend on clinical success and eventual approval or licensing. Until then, operating results remain disconnected from customer demand and product economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Expanded intellectual property protection
Broad issued and pending patent coverage can protect Aprea’s precision-oncology assets from competition and support future licensing or commercialization. Potential exclusivity into 2045–2047 strengthens the long-term strategic value of successful clinical candidates.
Read all positive factors
Aprea Therapeutics (APRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.00M
Dividend YieldN/A
Average Volume (3M)383.80K
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth-99.38%
EPS Growth53.42%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.29
Shares Outstanding12,591,136
10 Day Avg. Volume1,056,512
30 Day Avg. Volume383,804
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.73Price Target Upside292.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Aprea Therapeutics Business Overview & Revenue Model
Company Description
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The comp...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Aprea Therapeutics has historically not generated meaningful recurring revenue from product sales; its business model has primarily relied on financing to fund research and development. The company’s ...
Aprea Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.50M | 583.23K | 0.00 | 0.00 |
| Gross Profit | -5.43K | 0.00 | -7.86M | 576.18K | -16.40M | -271.68K |
| EBITDA | -12.29M | -12.58M | -12.94M | -14.28M | -37.37M | -36.86M |
| Net Income | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -36.54M |
Balance Sheet | ||||||
| Total Assets | 42.29M | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Cash, Cash Equivalents and Short-Term Investments | 41.23M | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K |
| Total Liabilities | 3.82M | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Stockholders Equity | 38.47M | 12.44M | 19.31M | 18.26M | 25.64M | 49.51M |
Cash Flow | ||||||
| Free Cash Flow | -12.18M | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Operating Cash Flow | -12.17M | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Investing Cash Flow | -15.75K | 0.00 | -15.48K | -93.09K | 0.00 | 0.00 |
| Financing Cash Flow | 36.89M | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
Aprea Therapeutics Technical Analysis
Neutral
0.95
Price Trends
0.72
Positive
0.78
Positive
0.82
Negative
Market Momentum
0.04
Negative
53.57
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Neutral. The current price of 0.95 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.72, and above the 200-day MA of 0.82, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 53.57 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APRE.
Aprea Therapeutics Risk Analysis
Aprea Therapeutics disclosed 78 risk factors in its most recent earnings report. Aprea Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aprea Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $10.00M | -0.62 | -46.72% | ― | -99.38% | 53.42% | |
52 Neutral | $14.58M | -0.49 | -304.87% | ― | ― | 98.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $6.03M | -0.35 | -41.95% | ― | ― | 99.50% | |
46 Neutral | $11.83M | -0.64 | -91.18% | ― | ― | 81.87% |
* Healthcare Sector Average
APRE
Aprea Therapeutics
0.79
-0.82
-50.68%
ERNA
Eterna Therapeutics
4.31
-26.69
-86.10%
QNRX
Quoin Pharmaceuticals
7.26
-0.36
-4.66%
NCNA
Nucana
1.40
-1.49
-51.56%
INAB
IN8bio
1.20
-0.96
-44.44%
Aprea Therapeutics Corporate Events
Business Operations and Strategy
Aprea Therapeutics Expands Global IP for Precision Oncology
Positive
Aug 28, 2026
On August 28, 2026, Aprea Therapeutics announced it had significantly expanded its global intellectual property portfolio supporting its precision oncology programs. The company now has 28 issued and 30 pending patents across its lead platforms, r...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aprea Therapeutics advances APR-1051 oncology pipeline progress
Positive
Aug 12, 2026
On August 12, 2026, Aprea Therapeutics reported second-quarter 2026 results and detailed progress across its oncology pipeline, led by WEE1 inhibitor APR-1051. The company is accelerating enrollment in the ACESOT-1051 Phase 1 trial, expanding from...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Aprea Shareholders Approve Directors, Reverse Split Flexibility
Positive
Jun 17, 2026
At its annual meeting of stockholders held on June 16, 2026, Aprea Therapeutics, Inc. reported that a quorum of approximately 66.8% of eligible shares was present and stockholders elected three Class I directors, Marc Duey, Richard Peters and Bern...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.